SML3706
BT2
≥98% (HPLC)
别名:
3,6-Dichloro-1-benzothiophene-2-carboxylic acid, 3,6-Dichlorobenzo[b]thiophene-2-carboxylic acid, 3,6-Dichlorobenzothiophene-2-carboxylic acid
登录 查看组织和合同定价。
选择规格
变更视图
关于此项目
经验公式（希尔记法）:
C9H4Cl2O2S
化学文摘社编号:
分子量:
247.10
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality Segment
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
[s]1c2c(c(c1C(=O)O)Cl)ccc(c2)Cl
InChI
1S/C9H4Cl2O2S/c10-4-1-2-5-6(3-4)14-8(7(5)11)9(12)13/h1-3H,(H,12,13)
InChI key
AAHPIJMQJAZYTM-UHFFFAOYSA-N
Biochem/physiol Actions
BT2 is an orally active, allosteric mitochondrial branched-chain α-ketoacid dehydrogenase (BCKD) kinase (BCKDK or BDK) inhibitor (IC50 = 3.19 μM) that induces BDK dissociation from the BCKD complex (BCKDC) with superior pharmacokinetics and metabolic stability than (S)-CPP. BT2 increases cellular BCKDC activity in cultures (40 μM; MEF & murine hepatocytes) and induces BDK degradation in mice & rats in vivo, effectively upregulating tissue BCKDC activity and downregulating plasma branched-chain amino acid (BCAA) level. Typical dosing range: 40-250 μM (in cultures or cell-free), 20-40 mg/kg (ip. or po. in vivo; mice & rats) or 200 mg/kg diet.
Orally active, allosteric mitochondrial branched-chain α-ketoacid dehydrogenase complex (BCKDC) kinase (BCKDK, BDK) inhibitor in vitro and in vivo.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable